AstraZeneca Shares Slump Amid Rumors of $400 Billion Bristol Myers Squibb Merger
AstraZeneca's stock fell significantly following market rumors of a potential $400 billion merger with Bristol Myers Squibb. Investors and analysts expressed skepticism about the strategic logic and potential benefits of such a large-scale pharmaceutical tie-up.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (79/100)Sources
AstraZeneca Investors See Little Logic in Bristol Tie-Up
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. (Source: Bloomberg)
Read full article →The $400bn megadeal brewing in big pharma
AstraZeneca’s talks with Bristol Myers Squibb could create the world’s fourth-largest drugmaker by market value
Read full article →Stocks mixed as AstraZeneca merger talk dents FTSE 100
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
By Jeremy Cutler
Read full article →Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”
Read full article →Coverage Timeline
Related Stories
US-Iran Military Escalation Sparks Retaliatory Strikes and Market Volatility
30m ago
BP Appoints Ian Tyler as New Chairman Following Leadership Transition
35m ago
Everus Construction and California Resources Finalize Major Corporate Acquisitions
54m ago
Nvidia Nears $14 Billion Acquisition of AI Startup Hugging Face
1h ago